These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 16445534)

  • 1. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
    Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
    J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
    Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment.
    Onda T; Yoshikawa H; Yasugi T; Matsumoto K; Taketani Y
    Jpn J Clin Oncol; 2010 Jan; 40(1):36-41. PubMed ID: 19820253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
    Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
    Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
    Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
    Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma.
    Liu EL; Mi RR
    Chin Med J (Engl); 2004 Oct; 117(10):1547-51. PubMed ID: 15498381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
    Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Maggioni A; Cosio S; Frassi E; LaPresa MT; Fuso L; Cristofani R
    J Clin Oncol; 2005 Feb; 23(4):751-8. PubMed ID: 15613698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.
    Bilici A; Salepci T; Dane F; Gumus M; Ustaalioglu BB; Seker M; Salman T; Turan C; Unal O; Yaylaci M
    Arch Gynecol Obstet; 2010 Oct; 282(4):417-25. PubMed ID: 20035339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
    Morice P; Dubernard G; Rey A; Atallah D; Pautier P; Pomel C; Lhommé C; Duvillard P; Castaigne D
    J Am Coll Surg; 2003 Dec; 197(6):955-63. PubMed ID: 14644284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neoadjuvant chemotherapy for advanced epithelial ovarian cancer].
    Hatae M; Onishi Y; Nakamura T; Yamamoto H; Kusumoto M; Matsui T; Mihara K; Taniguchi H
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1833-7. PubMed ID: 11729475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
    Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
    Capizzi E; Gabusi E; Grigioni AD; De Iaco P; Rosati M; Zamagni C; Fiorentino M
    Diagn Mol Pathol; 2008 Mar; 17(1):34-8. PubMed ID: 18303408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
    Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
    Colombo PE; Mourregot A; Fabbro M; Gutowski M; Saint-Aubert B; Quenet F; Gourgou S; Rouanet P
    Eur J Surg Oncol; 2009 Feb; 35(2):135-43. PubMed ID: 18289825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
    Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ovarian cancer].
    Onda T
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1735-9. PubMed ID: 18030006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.
    Vergote I; De Wever I; Tjalma W; Van Gramberen M; Decloedt J; van Dam P
    Gynecol Oncol; 1998 Dec; 71(3):431-6. PubMed ID: 9887245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
    Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
    Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.